ERN1 and ALPK1 inhibit differentiation of bi-potential tumor-initiating cells in human breast cancer

Citations Over TimeTop 21% of 2016 papers

Abstract

Cancers are heterogeneous by nature. While traditional oncology screens commonly use a single endpoint of cell viability, altering the phenotype of tumor-initiating cells may reveal alternative targets that regulate cellular growth by processes other than apoptosis or cell division. We evaluated the impact of knocking down expression of 420 kinases in bi-lineage triple-negative breast cancer (TNBC) cells that express characteristics of both myoepithelial and luminal cells. Knockdown of ERN1 or ALPK1 induces bi-lineage MDA-MB-468 cells to lose the myoepithelial marker keratin 5 but not the luminal markers keratin 8 and GATA3. In addition, these cells exhibit increased β-casein production. These changes are associated with decreased proliferation and clonogenicity in spheroid cultures and anchorage-independent growth assays. Confirmation of these assays was completed in vivo, where ERN1- or ALPK1-deficient TNBC cells are less tumorigenic. Finally, treatment with K252a, a kinase inhibitor active on ERN1, similarly impairs anchorage-independent growth of multiple breast cancer cell lines. This study supports the strategy to identify new molecular targets for types of cancer driven by cells that retain some capacity for normal differentiation to a non-tumorigenic phenotype. ERN1 and ALPK1 are potential targets for therapeutic development.

Related Papers

• → Breast cell invasive potential relates to the myoepithelial phenotype(2003)129 cited
• → Phenotypic Alterations in Myoepithelial Cells Associated With Benign Sclerosing Lesions of the Breast(2010)76 cited
• Morphological changes of myoepithelial cells of mouse lacrimal glands during postnatal development.(1995)
• → Basal clear cells of the normal human breast(1984)65 cited
• → Cellular adenomyoepithelioma of the breast(1983)10 cited